Dr Reddys Laboratories

The company's board also recommended a final dividend of Rs 30 per equity share of face value of Rs. 5 each for the financial year 2021-22.

It is a first-of-its-kind integrated and cashless digital health solution in India, the statement said

Apollo Hospitals and Dr Reddy's Laboratories on Monday said they are collaborating to initiate a COVID-19 vaccination programme in the country with Sputnik V.

Dr Reddy's Laboratories on Friday reported 29 per cent decline in consolidated net profit at Rs 557 crore for the fourth quarter ended March 31, 2021.

RDIF CEO Kirill Dmitriev in a virtual press conference recently said he expected over 50 million doses of SputnikV vaccine to be manufactured in India by this summer

Russian Covid-19 vaccine granted restricted emergency-use authorisation in India

The committee asked the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongoing Russian study

Containers with logos of Dr Reddy's and Sputnik V being unloaded from a small truck was seen

Such businesses outperform non-family firms by 3% in first six months of CY20, says Credit Suisse report

Steady improvement in the US and India market growth keeps analysts positive

In the absence of certificate, Dr Reddy's cannot export drug products to EU from Hyderabad facility

Recently, USFDA had issued a Form-483 with two observations after inspecting co's unit

The stock slipped 5% to Rs 2,602 on BSE in intra-day trade on back of heavy volumes.

The stock has fallen to its 52-week low of Rs 2,751, down 3.5% on BSE in early morning trade.

The stock dipped 5% to Rs 3,305 on the BSE.

The stock dipped 4% to Rs 3,465, extending its past two days 2% decline on the BSE.